3. Stage-directed treatment guidelines

Current Problems in Cancer

Volumn 20, Issue 3, 1996, Pages 157-178

  Langer, Corey ^a   Dresler, Carolyn ^a   Goldberg, Melvyn ^a   Movsas, Benjamin ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; REVIEW; UNITED STATES;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; PROGNOSIS; UNITED STATES;

EID: 0030133052     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0147-0272(96)80306-0     Document Type: Article

References (99)

1. Wingo T, Tong T. Bolden BA. Cancer statistics 1995. CA Cancer J Clin 1995:45:8-30.
2. Boring CC. Squires TS. Tang T. Cancer statistics, 1993. CA Cancer J Clin 1993:43:7-26.
3. Mountain CF. A new international staging system for lung cancer. Chest 1986:89(suppl):225S-33S.
4. Naruke T, Tomoyuki G, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. I Thorac Cardiovasc Surg 1988:96:440-7.
5. Ginsberg RJ. Kris MC, Armstrong |G. Cancer of the lung: non-small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott, 1993:673-723.
6. H. Martini N. Flohinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987:67:1037-49.
7. Patterson CA. Ginsberg RJ, Poon Y, Cooper JD. Goldberg M, Jones D. et al. A prospective evaluation of magnetic resonance imaging, computed tomography and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinomas. J Thorac Cardiovasc Surg 1987:94:679-84.
8. Ihde DC. Minna JD. Non-small cell lung cancer. Part II: treatment. Curr Probl Cancer 1991:15:61-104.
9. Rovario GC. Varoli F Rebultat C, et al. Trachéal sleeve pneumonoctomy lor bronchogenic carcinoma. I Thorac Cardiovasc Surg 1994:107:13-8.
10. O'Connell J, Kis M, Gralla R, et al. Frequency and prognostic importance of pre-treatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986:4:1604-14.
11. Mountain ( IF. McMurtrey MS. Frazier OU. Barkley HT, et al. Present status of postoperative adjuvant therapy for lung cancer. Cancer Bull 1980:32:108-12.
12. Moores D W, McKneally MF. Treatment of stage I lung cancer (TlNOMO, T2NOMO). Surg Clin North Am 1987:67:937-43.
13. Warren WH, Faber LP Segmentectomy versus lobectomv in patients with stage I pulmonary carcinoma. | Thorac Cardiovasc Surg 1994:107:1087-94.
14. Yano T. Yokoyama H, Yoshino I, Tayama K. Asoh H. Hata K, et al. Results of a limited resection for compromised or poor-risk patients with clinical stage I non-small cell carcinoma of the lung. ( Am Coll Surg 1995:181:33-7.
15. Van Houtte P. Rocmans P. Smcts P. Gofffin JC, Lustman-Maréchal J, Vanderhoett P. et al. Postoperative radial ion therapy in lung cancer: a controlled trial after resection of curative design. Int J Radial Oncol Biol Phys 1980:6:983-6.
16. Bloedorn FG. Cowley RA, Cuccia ÇA. et al. Preoperative irradiation in bronchogenic carcinoma. Am J Roentgenol Radium Ther Nucl Med 1964;92:77-87.
17. Warram J. Preoperative irradiation of cancer of the lung: final report of a therapeutic trial. Cancer 1975;36:914-25.
18. Feld R, Rubinstein L, Thomas FA. Adjuvant chemotherapy with cyclophosphamide, doxorubicin and cisplatin in patients with completely resected stage I non-small cell lung cancer. J Natl Cancer Inst 1993;85:299-306.
19. Niiranen A, Nitamo-Korhonen S, Kouri M, Assendelft A, Mattson K, Pyrhönen S. Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: a randomized study. J Clin Oncol 1992:10:1927-32.
20. Eastern Cooperative Oncology Group. Intergroup study of c/s-retinoic acid vs placebo in completely resected stage I NSCLC in the prevention of second primary malignancies, ECOG 91025.
21. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl f Med 1990:323:795-801.
22. Ayoub J, Vigneault J, Hanley A, et al. The Montreal multi-center trial in operable non-small cell lung cancer (NSCLC): a multivariate analysis of the predictors of relapse [abstract 846]. Proc Am Soc Clin Oncol 1991;10:247.
23. Mountain CE New prognostic factors in lung cancer: biologic prophets of cancer cell aggression. Chest 1995;108;246-54.
24. Bollen ECM, van Duin CJ, Theunissed PHMH, Hof-Grootenboer PE, Blijham GH. Mediastinal lymph node dissection in resected lung cancer: morbidity and accuracy of staging. Ann Thorac Surg 1993:55:961-6.
25. Martini N, Flehinger BJ, Nagasaki F Hart B. Prognostic significance of Nl disease in carcinoma of the lung. J Thorac Cardiovasc Surg 1983:86:646-53.
26. Holmes EC. Treatment of stage II lung cancer (T1N1, T2N1). Surg Clin North Am 1987:67:945-9.
27. Yano T, Yokoyama H, Inoue T, Asoh H, Tayama K, Ichinose Y. Surgical results and prognostic factors of pathologic N1 disease in non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1994;107:1398-402.
28. Weisenberger TH, Call M, Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986:315:1377-81.
29. Holmes EC, Gail M, Lung Cancer Study Group. Surgical adjuvant therapy for stage II and III adenocarcinoma and large cell undifferentiated carcinoma. J Clin Oncol 1986;4:710-5.
30. Lad T, Rubinstein A, Sadeghi A, et al. The benefit of adjuvant treatment for resected locally advanced non-small cell lung cancer. J Clin Oncol 1988:6:9-17.
31. Pichler JM, Pairolero PC, Weiland LH, et al. Bronchogenic carcinoma with chest wall invasion: factors affecting survival following en bloc resection. Ann Thorac Surg 1982;34:684-91.
32. McGaughan BC, Martini N, Bains MS, McCormack PM. Chest wall invasion in carcinoma of the lung: therapeutic and prognostic implications. J Thorac Cardiovasc Surg 1985;89:836-41.
33. Patterson GA, lives R, Ginsberg PJ, et al. The value of adjuvant radiotherapy in pulmonary and chest wall resection for bronchogenic carcinoma. Ann Thorac Surg 1982:34:692-7.
34. Paulson DL. The superior sulcus lesion. In: Delavne NC, Eschapasse H, editors. International trends in general thoracic surgery, vol I: lung cancer. Philadelphia: WB Saunders, 1985:121-31.
35. Ginsberg PJ Martini N, Zalman M, Armstrong JG, Bains MS, Burt ME, et al. Influence of surgical resection and brachytherapy in the management of superior sulcus tumor. Ann Thorac Surg 1994;57:1440-5.
36. Rosell R, Goméz-Codina J, Gamps G, Maestre J, Padille J, Gantró A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994:330:153-8.
37. Shields TW. The significance of ipsilateral mediastinal lymph node métastases (N2 disease) in non-small cell carcinoma of the lung. I Thorac Gardiovasc Surg 1990:99:48-53.
38. Goldstraw P, Mannam GC, Kaplan DK, Mitchail P. Surgical management of non-small cell lung cancer with ipsilateral mediastinal node métastases (N2 disease). I Thorac Gardiovasc Surg 1994:107:19-28.
39. Pearson FG, Delarue NC, lives R, et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. I Thorac Cardiovasc Surg 1982:83:1-11.
40. Watanabe Y, Shimizu J, Tsubota M. Iwa T Mediastinal spread of metastatic lymph nodes in bronchogenic carcinoma. Ghest 1990:97:1059.
41. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987:67:1037-49.
42. Mitsukuoka M, Hayashi A, Takamori S, Nagamatsu Y, Matsuo T, Kakegawa T. The significance of lymph nodes (LN) dissection through median sternotomy for left lung cancer. Lung Gancer 1994;ll(suppl 1):149.
43. Watanabe Y, Hayashi Y, Shimizu J. Oda M, Iwa T. Mediastinal nodal involvement and the prognosis of non-small cell lung cancer. Ghest 1991:100:422.
44. Levasseur PH, Regnard JK Long term results after surgery for N2 nonsmall cell lung cancer. Presented at the International Association for the Study of Lung Gancer (IASCC) Workshop, Burges, Belgium, June 17-21, 1990.
45. Naruke T. Goya T, Tsuchiya R, Suemasu K. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node métastases. Ann Thorac Surg 1988;46:603-1().
46. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. }Natl Cancer Inst 1994:86:681-8.
47. Martini N, Flehinger BJ Zaman MB, Beattie JB. Results of resection in nonoat cell carcinoma of the lung with mediastinal lymph node métastases. Ann Surg 1983:198:386-97.
48. Pearson FG. Radical surgery for N2 disease. Chest 1986;89(suppl):339-40.
49. Patterson GA, Piaza D, Pearson FG, et al. Significance of metastatic disease in subaortic lymph nodes. Ann Thorac Surg 1987:43:15-20.
50. Martini N, Kris MG, Gralla RJ, et al.The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node métastases (N2MO). Ann Thorac Surg 1988;45:370-9.
51. Martini N, Kris M, Flohinger BJ. et al. Preoperative chemotherapy of stage IIIA (N2) non-small cell lung cancer: the Memorial Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993:55:1365-74.
52. Ferez GA, Bauer M, Edelstein S, Gilespie BW, Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int ( Radial Oncol Biol Phys 1986:12:539-47.
53. Burkes RL. Shepherd FA. Ginsberg RJ. Blackstein ME, Goldberg ME, Todd T, et al. Induction chemotherapy with MVP in patients with stage IIIA (T1-3,N2,M0) unresectable non-small cell lung cancer: the Toronto experience [abstract]. Proc Am Soc Clin Oncol 1994;A:1078.
54. Burkes RL, Ginsberg RJ, Shepherd FA, Blackstein ME, Goldberg ME, Waters PE et al. Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresectable non-small cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992;10:580-6.
55. Perez CA, Pajak TF Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the RTOG. Cancer 1987;59:1874.
56. Petrovich Z, Stanley K, Cox JD, et al. Radiotherapy in the management of locally advanced lung cancer of all cell types. Cancer 1981:48:1335-40.
57. Perez CA, Stanley K, Grundy G, Hanson W, Rubin P, Kramer S, et al. Impact of irradiation techniques and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lungs: report by the Radiation Therapy Oncology Group. Cancer 1982;50;1091-9.
58. Ball D, Mathews J, Worotnink V, Crenna E. Longer survival with higher doses of thoracic radiotherapy in patients with limited non-small cell lung cancer. Int J Radiât Oncol Biol Phys 1993:25:599-604.
59. Douple EB, Richmond RC. Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor. Int J Radiât Oncol Biol Phys 1982;8:5015.
60. Begg AC, Stewart FA, Dewit L, et al. Interactions between cisplatin and radiation in experimental rodent tumors and normal tissues. In: Hill B, Bellamy A, editors. Antitumor drug-radiation interactions. Boca Raton, FL: CRC Press, 1989:154-510.
61. Schaake-Koning C, van den Bogoert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy in inoperable non-small cell lung cancer. N Engl J Med 1992:326:524-30.
62. Thames HD, Withers HR, Peters LJ, et al. Changes in early and late radiation responses with altered dose fractionation: implications for dose survival relationships. Int J Radiât Oncol Biol Phys 1982;8:219.
63. Fowler JF, Harai PM. Hyperfractionation's promise in cancer treatment. Contemp Oncol 1993:3:14.
64. Fowler JF Fractionation in radiation therapy. Semin Radiât Oncol 1992;2:16.
65. Withers HR, Thames HD, Peters LJ. Differences in the fractionation response of acutely and late-responding tissues. In: Kaercher KH, Kogelnik HD, Reinartz G, editors. Progress in radio-oncology; vol 2. New York: Raven Press, 1982:287.
66. Cox JD, Azarnia N, Byhardt R, Shin K, Emami B, Pajak TE A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with 69.6 Gy in favorable patients with radiation therapy oncology group stage III non-small cell lung cancer: report of the Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990:8:1543-55.
67. Saunders MI, Dische S. Continuous hyperfractionated accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus. Int J Radiât Oncol Biol Phys 1990:19:1211-5.
68. Lee JS, Komaki R, et al. Promising outcome of concurrent chemoradiation therapy with oral VP-16 and cisplatin for locally advanced, inoperable nonsmall cell lung cancer: RTOG 91-06 [abstract]. Proc Am Soc Clin Oncol 1995;14:.
69. Shaw EG. McGinnis WL, Jett JR, et al. Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small cell carcinoma of the lung. J Natl Cancer Inst 1993;85:321-3.
70. Jeremic B, Shibamoto Y, Acimovic L. Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer. J Clin Oncol 1995:13:452-8.
71. LeChevalier T. Arriagada R, Quoix K. et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomix.ed trial in 353 patients. J Natl Cancer Inst 1990:83:417-23.
72. LeChevalier T, Arriagada R, Quoix E. et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma [letter]. J Natl Cancer Inst 1992:84:58.
73. Dillman RO, Seagren SL, Fropert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990:323:940-5.
74. Dillman RO, Seagren SL, Herndon J, Green MR, et al. Randomized trial of induction chemotherapy plus radiation therapy (RT) vs RT alone in stage III non-small cell lung cancer: five-year follow up of CALGB 84-33 [abstract]. Proc Am Soc: Clin Oncol 1993;!2:329.
75. Sause WT. Scott G, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary advanced results of a phase III trial of regionally unresectable non-sinallcell lung cancer. J Natl Cancer Inst 1995:87:198-205.
76. Sause WT, Scott CB, Taylor S. et al. RTOG 8808, ECOG 4588: preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer with minimum three year follow up. Int I Radial Oncol Biol Phvs 1995;32(suppl l):108-9.
77. 'H. Chang AY, Kirn K. Click J. Anderson T. Karp D, Johnson D. Phase II study of taxol. merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Oncology Group results. I Natl Cancer Insl 1993:85:388-93.
78. Murphy WK. Fossella F, Winn RJ Shin DM, Hvnes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer, j Natl Cancer Inst 1993:85:384-8.
79. Choy H, Browne MJ. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol 1995;22(suppl 6):70-4.
80. Hei TK, Hall E). Taxol. radiation and oncogenic transformation. Cancer Res 1993:53:1368-72.
81. Langer C, Rosvold E. Kaplan R, Millenson M, Smith D, Kilpatrick D. et al. Induction therapy with paclitaxel and carboplatin followed by concurrent chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer; preliminary report of FCCC 94-001 [abstract], Proc: Am Soc Clin Oncol 1995:16:376.
82. Fukuoka M. Niitani H. Suzuki A, Molomiya M, Hasegawa K, Nichiwaki Y, et al. A plias II studv of CPT-11, a new derivative of campthothecin, for previously untreated non-small cell hing cancer. J Clin Oncol 1992;10:lti20.
83. Mattern MR. Hofmann GA, McCabe FL, lohnson RK. Synergistic cell killing by ionizing radiation and topoisomerase inhibitor lopotecan (SKF 104864). Cancer Res 1991:51:5813-6.
84. McDonald S. Chang AY. Rubini P. Wallenberg J, Kirn IS, Sobel S, et al. Combined betaseron R and radiation for inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993;27:613-9.
85. Rodriguez GI, Valdivieso M, von Hoff DD, Kraut M, Burris HA, Echardt JR, et al. Phase I/II trial of tirapazamine and cisplatin in patients with non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1995;16:382.
86. 1-difluorodeoxycytidine on the viability and radiosensitivity of EMT 6 cells in vitro. Oncol Res 1992;4:151-5.
87. Shields TW. Preoperative radiation therapy in the treatment of bronchial carcinoma. Cancer 1972,30:1388-94.
88. Kirschner PA. Lung cancer: preoperative radiation therapy and surgery. NY State J Med 1981;3:339-42.
89. Bonomi P, Faber LE Neoadjuvant chemoradiation therapy in non-small cell lung cancer: the Rush University experience. Lung Cancer 1993:9:383-90.
90. Langer CJ, Curran WJ, Keller SM. Catalano R, Fowler W, Blankstein K, et al. Report of phase II trial of concurrent chemoradiotherapy with radical thoracic coradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage III-B and bulky III-A non-small cell lung cancer. Int J Radiât Oncol Biol Phys 1993;26:469-78.
91. Fowler WC, Langer CJ, Curran WJ Jr, Keller SM. Preoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg 1993:55:986-9.
92. Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, McKenna R Jr, et al. Surgical resection of stage IIIA and stage IIIB NSCLC after concurrent induction chemotherapy: a SWOG trial. J Thorac Cardiovasc Surg 1993:105:97-106.
93. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrissi AT, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995:13:1880-92.
94. Fleck J, Camargo J, Godoy D, Teixeira P, Braga Filho A, Barletta A, Ferreira R et al. Chemoradiation therapy (CRT) versus chemotherapy (CT) alone as a neoadjuvant treatment for stage III non-small cell lung cancer (NSCLC): preliminary report of a phase III prospective, randomized trial [abstract]. Proc Am Soc Clin Oncol 1993;12:333.
95. Evans WK, Will BE Berthelot JM, Walton MC. The cost of managing lung cancer in Canada. Oncology;1995;9(suppl):ll.
96. Evans WK, Will BR Wolfson MC. et al. Microsimulation modelling of the costs of standard and new treatment approaches in non-small cell lung cancer (NSCLC) [abstract 986]. Proc Am Soc Clin Oncol 1992:11:25.
97. Green MR, Lillenbaum RC. Stage IIIA category of non-small cell lung cancer: a new proposal. J Natl Cancer Inst 1994:86:586-8.
98. Bulzebruck H, Bopp R, Brings P, et al. New aspects in the staging of lung cancer: prospective validations of the International Union Against Cancer TNM classification. CA J Cancer Clin 1992:70:1102-10.
99. Watanabe Y, Shimizu J, Oda M, et al. Proposals regarding some deficiencies in the new International Staging System for non-small cell lung cancer. Jpn J Clin Oncol 1991:21:160-8.